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ABSTRACT
Background: Canine vector borne diseases (CVBD) are common in tropical countries where the climate favors arthropods 
abundance. Comorbidity with one or more CVBD are reported as clinical complication and worsen prognostic. Canine 
visceral leishmaniosis (CanL) is an endemic zoonotic disease in Brazil caused by Leishmania infantum, with several res-
trictions to canine treatment and suggestion of reservoirs euthanasia for disease control. Heartworm (HW) is a helminthic 
disease caused by Dirofilaria immitis infection in dogs. It is a chronic heart disease, which can lead to death by congestive 
heart failure. Canine ehrlichiosis (CE) is caused by Ehrlichia canis bacterial infection with a zoonotic potential and fatal 
to dogs in acute and chronic presentations. Exposed the above, this study aims to describe a successful treatment and 
management of a dog with CanL, CE, and HW comorbidity.
Case: A 3-year-old male uncastrated black Labrador dog, weighing 35 kg, was admitted to the veterinary clinic due to 
immunochromatographic CanL positive test performed by municipal zoonosis control center active surveillance. Clinical 
exam showed a mild shedding, intermittent eye white/yellow discharge and popliteal lymph nodes enlargement. After 
positive for CanL, veterinary requested more laboratorial exams. IFAT and ELISA were positive for CanL, blood smear 
showed presence of microfilaria, and bone marrow cytology showed Ehrlichia spp. morulae and microfilaria. Initial treat-
ment prescribed was oral doxycycline, omeprazole, ranitidine, and domperidone for 30 days, and allopurinol and ivermectin 
until further recommendation. Additionally, repellent collar, repellent spray and vitamin supplement was indicated. After 
first month, marbofloxacin for 30 days and three doses of immunostimulant drug were administrated. After three months 
of treatment, dog still positive for heartworm, ehrlichiosis, and CanL. Doxycycline protocol was repeated. Dog became 
consistently negative for all pathogens one year later with persistent thrombocytopenia but without clinical signs, ergo 
allopurinol and ivermectin were discontinued. After 4 years of follow up, the animal had an acute pancreatitis and died, 
with unremarkable total blood count and negative for all pathogens.
Discussion: CVBD coinfections are commonly reported as worsen prognostic in endemic regions. The pathogens reported 
here share a host immunomodulation competence. L. infantum and Ehrlichia spp. downregulates Th1 response, whereas 
D. immitis increase as Th2 profile. The therapeutic protocol was iniciated by staging CanL. Since the patient had clinical 
signs, allopurinol was prescribed as a well-established drug for CanL. Marbofloxacin was added due to its high safety 
drug in clinical improvement of infected dogs with and without renal disease and in vitro effectiveness against L. infantum. 
Domperidone was used to promote Th1 cytokine profile as INF-γ, IL-2, IL-12, and TNF-α. We used an immunostimulant 
protocol to favor polarization to the Th1 profile comprised by 30 days of domperidone protocol followed by a vaccine and 
an immunomodulator. Doxycycline was used successfully for Ehrlichia spp. and HE clearance after 2 treatment courses 
and 1 year of ivermectin every 15 days. The animal presented intermittent coughing episodes on the first treatment course, 
but no medical intervention was needed besides exercise restriction. Our report shows the successful management of one 
dog with CanL, CE and HE comorbidity. This success was possible due to early detection and good therapeutic choice.
Keywords: canine visceral leishmaniosis, coinfection, Dirofilaria immitis, Erhlichia canis, Leishmania infantum, treatment.
2
A. Leal-Lima, T.C. Ferreira, T.M.V. Ferreira, P.C. Coelho & D.C.S. Nunes-Pinheiro. 2021. Successful Treatment and 
Management of Canine Ehrlichiosis-Leishmaniosis-Heartworm Comorbidity. Acta Scientiae Veterinariae. 49(Suppl 1): 687.
INTRODUCTION
Canine visceral leishmaniosis (CanL), ehrli-
chiosis (CE) and heartworm (HW) are examples of 
canine vector-borne diseases (CVBD) endemic in 
Brazil [4,13,27]. Comorbidity is related to worsen 
prognosis, thus early diagnostic is crucial to avoid 
critical illness [2,31].
Dogs with CanL or CE can be apparently 
healthy or present a broad of alterations including 
dermatitis, emesis, lymph nodes enlargement, and 
conjunctivitis.  They are caused by Leishmania in-
fantum and Ehrlichia canis infection, transmitted by 
Lutzomiya longipalpis sandfly and by Rhipicephalus 
sanguineus tick respectively [18,28].
Treatment of CanL needs assorting stage 
accordingly, since animals in early stages have good 
prognosis [6,28]. Additionally, dogs without clinical 
signs are related to lower transmission of the parasite 
to the vector [15]. Doxycycline is recommended to 
treat CE, it is efficient in clinical signs remission but 
can be repeated to clear infection [18,34].
Canine HW is caused by Dirofilaria immitis 
nematodes and transmitted by mosquito species, in-
cluding Aedis, Anopheles, and Culex [9,29]. The adult 
worms parasitize pulmonary arteries and right heart 
chambers. Disease presentation will depend on parasite 
load, normally dogs remain without clinical signs with 
detectable microfilaria on blood smear, but cough and 
exercise intolerance can be observed [5]. Alternative 
slow killing treatment with macrocyclic lactone and 
doxycycline are reported [3,16].
These 3 CVBD cited can have silent infection 
or severe chronic diseases presentation. Therefore, 
the aim of this case report is to describe a successful 
treatment and management of a dog with CanL, CE, 
and HW comorbidity.
CASE
A 3-year-old male uncastrated black Labrador 
dog, weighing 35 kg, was admitted to the veterinary 
clinic due to immunochromatographic CanL positive 
test1 (Dual Path Plataform®) performed by municipal 
zoonosis control center active surveillance in August 
2014. Thereafter, dog was positive for CanL on IFAT 
(1:80), and ELISA, and for Ehrlichia spp. morulae 
and microfilaria on bone marrow cytology. Clinical 
exam showed a mild hair loss, popliteal lymph nodes 
enlargement, hyperemia mucous membranes, and 
intermittent eye discharge. Nonetheless the animal 
was active, normal temperature, and appetite. Total 
blood count, sera levels of creatinine, urea, and alanine 
aminotransferase were unremarkable, but microfilaria 
was observed on blood smear (Table 1 and Table 2).
An Ehrlichia spp. infection was reported one 
year before (2013), but no confirmatory diagnostic was 
done previously or after treatment. At the time, emesis, 
lack of appetites, alopecia, lymph node enlargement, 
and fever were detected on clinical exam. Dog was 
treated with intramuscular tetracycline injections for 
21 days. Diagnostic and clinical management was done 
monitoring clinical improvement, platelet morphology 
and count (Table 1). Treatment was finished and the 
dog was healthy until August 2014.
Figure 1. Picture of the dog in August 2014 showing hyperemic mucous membranes and mild alopecia.
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Initial treatment prescribed was oral doxycy-
cline2 [Doxitrat® - 10 mg/kg, VO, SID for 28 days] for 
HW and CE. Omeprazole3 [Medley® - 1 mg/kg, VO, 
SID for 35 days] and ranitidine3 [Medley® - 2 mg/kg, 
VO, BID for 30 days] were administrated to avoid 
gastritis, and ivermectin2 [Mectimax® - 6 µg/kg, VO, 
once every 15 days until clearance of D. immitis].
No parasitological or laboratorial exams subs-
tantiate prescription of leishmanicidal drugs, despite 
positive in 3 serological tests (Table 2). Therefore, 
dog was categorized as CanL stage I and therapy 
was prescribed as follows: domperidone4 [EMS® - 
0.5 mg/kg, VO, SID for 30 days], allopurinol3 [Medley® 
- 10 mg/kg, VO, SID until further recommendation]. 
Additionally, repellent collar5 (Scalibor®), repellent 
spray6 (Karflae Citronela®), and vitamin supplement7 
(Glicopan Pet®) were indicated. Dog showed intermit-
tent emesis and coughs during this first protocol, even 
with exercise restriction.
After doxycycline and domperidone protocol 
(30 days of treatment), marbofloxacin8 [Marbopet® - 
3 mg/kg VO, SID for 30 days], and 3 subcutaneous 
doses of commercial immunomodulator8 [Infervac® 
- 2 mL] plus CanL vaccine8 [Leishtec® - 2 mL] once 
every 21 days were administrated. During this period, 
emesis and coughing episodes decreased.
In November 2014 (72 days of treatment), 
blood and bone marrow smear were negative for 
microfilaria (Table 2), but platelet count was lower 
compared to August 2014 and giant platelets were 
observed (Table 1). Serological tests for heartworm and 
CanL were positive, and bone marrow smear revealed 


































4.42 5.09 6.05 7.02 6.08 7.04 6.53 6.08 6.02 6.67 6.46 7.72 6.91 7.72
Hb 
(g/dL)
10 13.8 15.5 16.1 13.8 16.7 15.1 14.1 13.6 15.5 15.1 17.6 16.2 19.9
Hct 
(%)
31.1 38 45.3 49.9 43 50.6 45.1 43.8 39.7 47.4 45.8 52.1 46.9 52.9
WBC 
(x103/µL)
8.4 18.8 16.9 13.0 19.0 19.2 18.0 19.7 11.0 17.6 19.6 14.6 12.9 16.8
Plt 
(x103/uL)
63 128 210 167 196 160 169 108 117 106 163 125 205 576
Plt 
Mor
GP GP n n GP GP GP n GP n GP n n n
TPP 
(g/L)
6.6 7.2 7 7 6.8 7.2 7 7.4 7.2 7.4 7.6 8 8.4 14
Creat. 
(mg/dL)
- - 1.2 1.29 - 1.02 - 1.2 0.98 - - 0.86 - 1.3
BUN 
(UI/dL)
- - 50.9 49.0 - 24.0 - - - - - - - 30.0
ALT 
(UI/L)
- 101 54 56 - 55 - 88 24.1 - - 329 - 210
*Treatment started at August 2014. RBC: red blood cells; Hb: hemoglobin; Hct: hematocrit; WBC: White blood cells; Plt: Platelet count; Plt Mor: Platelet 
morphology; TPP: Total plasma proteins; Creat: serum creatinine; Blood urea nitrogen; ALT: alanine aminotransferase; GP: Giant platelets; n: Normal; 
-: Non available.
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Ehrlichia spp. morulae (Table 2). Thus, doxycycline 
with omeprazole protocol was repeated in a lower dose 
[7.5 mg/kg, 1 mg/kg VO, SID for 28 days respecti-
vely]. On this second treatment course, dog showed 
improved exercise tolerance and no emesis. Ivermectin, 
allopurinol, vitamin supplement, repellent collar, and 
spray were maintained until September 2015, when 
serological HW and CanL test were negative (Table 2).
After one year of clinical management, dog 
became consistently negative for all pathogens with 
persistent thrombocytopenia (Table 1 and 2). From 
2015 until 2018, the patient did not show coughing, eye 
discharge or emesis, with exercise tolerance, appetite 
and healthy. In September 2018, dog was admitted to 
the clinic because of a lack of appetite and emesis. 
Acute pancreatitis was diagnosed by abdominal ultra-
sonography causing death of the animal with unrema-
rkable total blood count and negative for all pathogens, 
including L. infantum whole blood PCR (Table 2).
DISCUSSION
This study shows a dog that lived for years after 
CanL, HW, and CE comorbidity remission after treat-
ment according to the literature. These diseases have 
severe chronical presentations but favorable prognosis 
in early diagnosis [6,28].
CVBD coinfections are commonly reported as 
worsen prognostic in endemic regions, where vectors 
are abundant allowing higher transmission rates [10,31]. 
The pathogens reported here share a host immunomodu-
lation competence. Leishmania infantum and Ehrlichia 
spp. downregulate Th1 response and macrophages 
killing effectiveness, by different pathways, resulting in 
pathogen intracellular survival and replication [14,32]. 
Hence, a mammal infected by one organism can be 
more susceptible to infection with the other. Dirofilaria 
immitis can immunomodulate the host by increasing 
Th2 profile which downregulates Th1 response, favo-
ring an infection by intracellular pathogens, such as 
Ehrlichia spp. and Leishmania spp. [17]. On our report, 
the order of events cannot be stablished, but certainly 
these CVBD are favored by climate, vector/pathogen 
abundance and/or host immunomodulation.
The therapeutic protocol iniciated by staging 
the CanL which the patient can be classified in 4 
or 5 stages. According Leishvet [28] and Brasileish 
group [6], our patient had good prognosis classified 
as stage I and stage II, respectively. Recommended 
treatment ranges from scientific neglect to allopurinol, 
immunotherapy, immunomodulation, and miltefosine 
[6,28]. Since the patient had clinical signs, allopurinol 
was prescribed as a well-established drug for CanL. 
Table 2. Parasitological, serological, and molecular tests (2013-2018) of a 3-year-old male uncastrated black Labrador dog (2013-2018) with leishmani-
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- - E - N - - - - - -
HW S - - - - - Pos - Pos - N - - - -
IFAT - -  1:80 - N  1:40 - N N N N N N N
ELISA - - Pos - N Pos - N N N N N N IND
PCR - - - - - - - - - - - - N N
*Treatment started at August 2014. DPP®: Immunochromatographic Dual Path Plataform for Leishmanina infantum; Bone Marrow Cyt: Bone marrow 
cytology; HW S: Hear worm serological test; IFAT: Immunofluorescence antibody test for Leishmania infantum; ELISA: Enzyme-linked immunosorbent 
assay for Leishmania infantum; n: Normal; -: Non available; N: Negative; MF: Microfilaria observed; E: Ehrlichia spp. morulae observed; Pos: positive; 
IND: indeterminate; PCR: Whole blood polymerase chain reaction for Leishmania spp. 
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Marbofloxacin was added in therapeutic as an alternati-
ve drug for CanL due to its high safety drug in clinical 
improvement of infected dogs with and without renal 
disease [22,25]. Furthermore, in vitro effectiveness 
against L. infantum strains was reported [1,11].
Domperidone was used on recommended low- 
secure dose [0.5 mg/kg, VO, SID, for 30 days] for its 
results on clinical remission and prevention of CanL. 
This drug increases prolactin serum level, and this 
hormone has been related to promote Th1 cytokine 
profile as INF-γ, IL-2, IL-12, and TNF-α [26,33]. Im-
munotherapeutic approaches are reported as efficient 
on preventing disease progression in CanL stages I and 
II [30]. These protocols are based on switching Treg 
or Th2 to a Th1 profile, enhancing parasite clearance 
[23,24]. Here we used an immune stimulant protocol 
to polarize Th1 patient response comprised by 30 
days of domperidone protocol followed by a vaccine 
with A2 Leishmania antigen conjugated with saponin 
(Leishtec®), an immunomodulator (Infervac®), with 
Escherichia coli lipopolysaccharide and inactivated 
cells of Propionibacterium acnes. This protocol was 
repeated annually.
Prognostic of CE and HW is good when de-
tected early and doxycycline is a recommended drug 
for CE and HW, thus was prescribed on the initial 
treatment. Doxycycline is efficient for CE in clinical 
improvement but may not clear infection in one treat-
ment course. Hence, repeating the treatment is sugges-
ted before using alternative drug since Ehrlichia spp. 
resistance to tetracycline derivatives was not reported 
[18]. On our study, prescribed protocol for Ehrlichia 
spp. did not clear the bacterial infection in one cour-
se, therefore it was repeated after two months being 
successful despite lowering the dose.
A long-term alternative treatment for HW 
is association of doxycycline with ivermectin [21]. 
Here we report a patient diagnosed with D. immitis 
by  visualization of microfilaria on blood smear (Table 
2). Echodopplercardiography was done in September 
2014, but no adult worms were visualized. The alterna-
tive treatment chosen suggests ivermectin continuous 
use until seroconversion, since microfilaremia clearan-
ce occurs before death of adult worms.
On our case, doxycycline was used success-
fully for Ehrlichia spp. and HE clearance after two 
treatment courses and one year of ivermectin every 
15 days. The animal presented intermittent coughing 
episodes on the first treatment course, but no medical 
intervention was needed besides exercise restriction. 
It is noteworthy the persistent thrombocytopenia after 
detection and treatment of the comorbidity (Table 1). 
Low platelet count is reported in E. canis, D. immitis, 
and L. infantum infection and several mechanisms are 
described such as immune mediated destruction, dys-
function, splenic sequestration via complement biding 
and vasculitis [7,12,20,27]. The exact mechanism that 
occurred on this report was not investigated. Regardless 
of the low platelet count, as the dog became clinically 
healthy and negative on all tests used, therapeutic 
intervention with ivermectin or allopurinol were not 
supported after one year. 
Our report shows the successful management 
of one dog with CanL, CE and HE comorbidity. This 
success was possible due to early detection and good 
therapeutic choice. The authors also reinforce the 
importance of performing differential diagnosis for 
CVBD in endemic areas, regardless of one infection 
detected, other pathogens may infect the same animal, 
and treatment success will depend on commitment of 
veterinary practitioner to find these pathogens. Additio-
nally, prevent vectors on an infected/suspected animal 
is ethically fundamental to avoid zoonotic transmission. Figure 2. Picture of the dog in December 2017 showing wellness. 
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